A clinical-stage biotechnology company developing cell and exosome-based therapies for rare diseases, with a primary focus on treating Duchenne muscular dystrophy–related cardiomyopathy. Its lead candidate, deramiocel, is being studied to address cardiac complications associated with Duchenne, a key...
1 member of Congress has disclosed 2 trades in Capricor Therapeutics, Inc. (CAPR), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-07-27 | Roger W. Marshall | sell | $1K – $15K |
| 2017-07-27 | Roger W. Marshall | buy | $1K – $15K |